Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.

Woo CJ, Maier VK, Davey R, Brennan J, Li G, Brothers J 2nd, Schwartz B, Gordo S, Kasper A, Okamoto TR, Johansson HE, Mandefro B, Sareen D, Bialek P, Chau BN, Bhat B, Bullough D, Barsoum J.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1509-E1518. doi: 10.1073/pnas.1616521114. Epub 2017 Feb 13.

2.

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.

Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26.

PMID:
22837008
3.

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.

Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17.

4.

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.

Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Lu R, Blackman RK, Barsoum J, Koya K, Wada Y.

Free Radic Biol Med. 2012 May 15;52(10):2142-50. doi: 10.1016/j.freeradbiomed.2012.03.017. Epub 2012 Apr 17.

PMID:
22542443
5.

Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.

Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, Tatsuta N, Jacobson E, Barsoum J, Krueger JG.

PLoS One. 2012;7(4):e35069. doi: 10.1371/journal.pone.0035069. Epub 2012 Apr 6.

6.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

7.

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J.

PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3.

8.

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK.

PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.

9.

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.

Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.

Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.

10.

Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.

Qu Y, Wang J, Sim MS, Liu B, Giuliano A, Barsoum J, Cui X.

Breast Cancer Res Treat. 2010 Jun;121(2):311-21. doi: 10.1007/s10549-009-0470-6. Epub 2009 Jul 16.

PMID:
19609669
11.

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA.

Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660.

12.

Elesclomol induces cancer cell apoptosis through oxidative stress.

Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J.

Mol Cancer Ther. 2008 Aug;7(8):2319-27. doi: 10.1158/1535-7163.MCT-08-0298.

13.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.

Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26.

14.

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.

Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L, Wu Y, Qin J, Balasubramanyam V, Barsoum J, Ono M.

Blood. 2007 Feb 1;109(3):1156-64. Epub 2006 Oct 19.

PMID:
17053051
15.

Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat.

Dass B, Iravani MM, Huang C, Barsoum J, Engber TM, Galdes A, Jenner P.

J Neural Transm (Vienna). 2005 Jun;112(6):763-78. Epub 2004 Dec 10.

PMID:
15586304
16.

Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Choi EA, Lei H, Maron DJ, Mick R, Barsoum J, Yu QC, Fraker DL, Wilson JM, Spitz FR.

Clin Cancer Res. 2004 Feb 15;10(4):1535-44.

17.

Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.

Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR.

Cancer Res. 2003 Sep 1;63(17):5299-307.

18.

Direct evidence that IFN-beta functions as a tumor-suppressor protein.

Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ.

J Interferon Cytokine Res. 2002 Nov;22(11):1089-98.

PMID:
12513908
19.

Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.

Brickelmaier M, Carmillo A, Goelz S, Barsoum J, Qin XQ.

J Interferon Cytokine Res. 2002 Aug;22(8):873-80.

PMID:
12396726
20.

CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice.

Brown JL, Barsoum J, Qin XQ.

J Interferon Cytokine Res. 2002 Jun;22(6):719-28.

PMID:
12162884
21.

Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models.

Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J.

Mol Ther. 2001 Oct;4(4):356-64.

22.

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.

Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM.

Cancer Res. 2001 Aug 15;61(16):6201-12.

23.

Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, Liu W, Ellis L, Moscioni AD, Tazelaar J, Fawell S, Qin X, Propert KJ, Davis A, Fraker DL, Wilson JM, Spitz FR.

J Clin Invest. 2001 Jul;108(1):83-95.

24.

Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver.

Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE.

Mol Ther. 2001 Jan;3(1):28-35.

25.

Sevelamer, Ca x P product and vitamin D.

Fournier A, Barsoum J, Fickl R, Oprisiu R, El Esper N, Moriniere P.

Nephrol Dial Transplant. 2001 Feb;16(2):429-30. No abstract available.

PMID:
11158431
26.

Baculovirus vector requires electrostatic interactions including heparan sulfate for efficient gene transfer in mammalian cells.

Duisit G, Saleun S, Douthe S, Barsoum J, Chadeuf G, Moullier P.

J Gene Med. 1999 Mar-Apr;1(2):93-102.

PMID:
10738573
27.

Concentration of recombinant baculovirus by cation-exchange chromatography.

Barsoum J.

Biotechniques. 1999 May;26(5):834-6, 838, 840. No abstract available.

28.

Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14411-6.

29.
30.

Interferon-beta induces S phase accumulation selectively in human transformed cells.

Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J.

J Interferon Cytokine Res. 1997 Jun;17(6):355-67.

PMID:
9198003
31.

Differential cell cycle effects induced by E2F1 mutants.

Qin XQ, Barsoum J.

Oncogene. 1997 Jan 9;14(1):53-62.

32.

Sequences flanking the core DNA-binding domain of bovine papillomavirus type 1 E2 contribute to DNA-binding function.

Pepinsky RB, Prakash SS, Corina K, Grossel MJ, Barsoum J, Androphy EJ.

J Virol. 1997 Jan;71(1):828-31.

33.

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens.

Moy P, Daikh Y, Pepinsky B, Thomas D, Fawell S, Barsoum J.

Mol Biotechnol. 1996 Oct;6(2):105-13.

PMID:
8970166
34.
35.

Endosomolytic activity of cationic liposomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (TAT) to mammalian cells.

Huang L, Farhood H, Serbina N, Teepe AG, Barsoum J.

Biochem Biophys Res Commun. 1995 Dec 26;217(3):761-8.

PMID:
8554596
36.

Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin.

Chen LL, Frankel AD, Harder JL, Fawell S, Barsoum J, Pepinsky B.

Anal Biochem. 1995 May 1;227(1):168-75.

PMID:
7668378
37.

Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes.

Farhood H, Gao X, Barsoum J, Huang L.

Anal Biochem. 1995 Feb 10;225(1):89-93.

PMID:
7778790
38.

Tat-mediated delivery of heterologous macromolecules into living cells.

Barsoum J, Moore C, Seery J, Daikh Y, Chen LL, Corina K, Moy P, Brown R, Shapiro R, Taylor F, Androphy E, Pepinsky B, Fawell S.

Restor Neurol Neurosci. 1995 Jan 1;8(1):11-2. doi: 10.3233/RNN-1995-81203. No abstract available.

PMID:
21551797
39.

Stable integration of vectors at high copy number for high-level expression in animal cells.

Barsoum J.

Methods Mol Biol. 1995;48:225-37. No abstract available.

PMID:
8528394
40.

Specific inhibition of a human papillomavirus E2 trans-activator by intracellular delivery of its repressor.

Pepinsky RB, Androphy EJ, Corina K, Brown R, Barsoum J.

DNA Cell Biol. 1994 Oct;13(10):1011-9.

PMID:
7945933
41.

Cationic liposomes for direct gene transfer in therapy of cancer and other diseases.

Farhood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, Barsoum J, Bottega R, Epand RM.

Ann N Y Acad Sci. 1994 May 31;716:23-34; discussion 34-5. Review.

PMID:
8024197
42.

Tat-mediated delivery of heterologous proteins into cells.

Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J.

Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8.

43.

The tryptophan bridge is a critical feature of the papillomavirus E2 DNA binding domain.

Corina K, Grossman SR, Barsoum J, Prakash SS, Androphy EJ, Pepinsky RB.

Virology. 1993 Nov;197(1):391-6.

PMID:
8212573
44.

Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding.

Barsoum J, Prakash SS, Han P, Androphy EJ.

J Virol. 1992 Jun;66(6):3941-5.

45.

Transactivation of heterologous promoters by HIV-1 tat.

Han P, Brown R, Barsoum J.

Nucleic Acids Res. 1991 Dec;19(25):7225-9.

46.
47.

Trans activation by the bovine papillomavirus E2 protein in Saccharomyces cerevisiae.

Morrissey LC, Barsoum J, Androphy EJ.

J Virol. 1989 Oct;63(10):4422-5.

48.
49.

Supplemental Content

Loading ...
Support Center